Driving Timely Biomarker Testing to Optimize Treatment Decisions for Colorectal Cancer Patients Grant

Driving Timely Biomarker Testing to Optimize Treatment Decisions for Colorectal Cancer Patients Grant

Status: ACTIVE
Funder: Pfizer, Inc.
Amount: Up to C $100,000
Last Updated: January 22, 2026

Summary

Overview

Pfizer Pfizer supports the global healthcare community’s independent initiatives (e.g., research, quality improvement or education) to improve patient outcomes in areas of unmet medical need that are aligned with Pfizer’s medical and/or scientific strategies. Colorectal Cancer Canada Colorectal Cancer Canada (CCC) is Canada’s patient led not-for-profit patient association dedicated to colorectal cancer awareness and education, support for patients and their caregivers, and advocacy on their behalf and aspires to reduce the incidence and mortality of colorectal cancer in Canada while improving the quality of life of patients, their families and their caregivers. Driving Timely Biomarker Testing to Optimize Treatment Decisions for Colorectal Cancer Patients Across Canada The intent of this RFP is to encourage the applicant Canadian organizations and institutions to pursue innovative approaches for Research or QI projects that aim to optimize biomarker testing for patients in CRC at the applicants’ centre. Applicants are invited to implement innovative ideas with the goal of creating a path for sustainable biomarker testing for mCRC patients in Canada. • Applicants must submit a Research or QI project budget for a maximum of C$100,000.

Eligibility

We've imported the main document for this grant to give you an overview. You can learn more about this opportunity by visiting the funder's website.